vs
碧迪（BDX）与FISERV INC（FISV）财务数据对比。点击上方公司名可切换其他公司
FISERV INC的季度营收约是碧迪的1.0倍（$5.3B vs $5.3B），FISERV INC净利率更高（15.3% vs 7.3%，领先8.1%），FISERV INC同比增速更快（0.6% vs -0.4%），FISERV INC自由现金流更多（$1.5B vs $549.0M），过去两年FISERV INC的营收复合增速更高（4.0% vs 2.0%）
碧迪（Becton Dickinson）是美国跨国医疗科技企业，核心业务包括研发、生产及销售医用器械、仪器系统与试剂产品，同时在特定领域提供专业咨询及数据分析服务，业务覆盖全球多国，在全球医疗技术领域具备领先地位。
Fiserv是总部位于美国威斯康星州密尔沃基的跨国金融科技企业，面向银行机构提供借记卡、信用卡交易处理、忠诚度计划管理、贷款服务、电子账单支付、电汇及ACH转账、支票存款、ATM交易处理等解决方案，同时生产借记卡、信用卡及POS终端设备。
BDX vs FISV — 直观对比
营收规模更大
FISV
是对方的1.0倍
$5.3B
营收增速更快
FISV
高出1.0%
-0.4%
净利率更高
FISV
高出8.1%
7.3%
自由现金流更多
FISV
多$953.0M
$549.0M
两年增速更快
FISV
近两年复合增速
2.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $5.3B | $5.3B |
| 净利润 | $382.0M | $811.0M |
| 毛利率 | 45.9% | — |
| 营业利润率 | 10.5% | 24.4% |
| 净利率 | 7.3% | 15.3% |
| 营收同比 | -0.4% | 0.6% |
| 净利润同比 | 24.0% | -13.5% |
| 每股收益（稀释后） | $1.34 | $1.51 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDXFISV
| Q4 25 | $5.3B | $5.3B | ||
| Q3 25 | $5.9B | $5.3B | ||
| Q2 25 | $5.5B | $5.5B | ||
| Q1 25 | $5.3B | $5.1B | ||
| Q4 24 | $5.2B | $5.3B | ||
| Q3 24 | $5.4B | $5.2B | ||
| Q2 24 | $5.0B | $5.1B | ||
| Q1 24 | $5.0B | $4.9B |
净利润BDXFISV
| Q4 25 | $382.0M | $811.0M | ||
| Q3 25 | $493.0M | $792.0M | ||
| Q2 25 | $574.0M | $1.0B | ||
| Q1 25 | $308.0M | $851.0M | ||
| Q4 24 | $303.0M | $938.0M | ||
| Q3 24 | $400.0M | $564.0M | ||
| Q2 24 | $487.0M | $894.0M | ||
| Q1 24 | $537.0M | $735.0M |
毛利率BDXFISV
| Q4 25 | 45.9% | — | ||
| Q3 25 | 47.5% | — | ||
| Q2 25 | 47.8% | — | ||
| Q1 25 | 42.8% | — | ||
| Q4 24 | 43.2% | — | ||
| Q3 24 | 45.7% | — | ||
| Q2 24 | 46.2% | — | ||
| Q1 24 | 45.7% | — |
营业利润率BDXFISV
| Q4 25 | 10.5% | 24.4% | ||
| Q3 25 | 11.8% | 27.3% | ||
| Q2 25 | 16.0% | 30.7% | ||
| Q1 25 | 10.4% | 27.2% | ||
| Q4 24 | 8.8% | 31.8% | ||
| Q3 24 | 11.4% | 30.7% | ||
| Q2 24 | 12.1% | 28.0% | ||
| Q1 24 | 14.5% | 24.2% |
净利率BDXFISV
| Q4 25 | 7.3% | 15.3% | ||
| Q3 25 | 8.4% | 15.0% | ||
| Q2 25 | 10.4% | 18.6% | ||
| Q1 25 | 5.8% | 16.6% | ||
| Q4 24 | 5.9% | 17.9% | ||
| Q3 24 | 7.4% | 10.8% | ||
| Q2 24 | 9.8% | 17.5% | ||
| Q1 24 | 10.6% | 15.1% |
每股收益（稀释后）BDXFISV
| Q4 25 | $1.34 | $1.51 | ||
| Q3 25 | $1.71 | $1.46 | ||
| Q2 25 | $2.00 | $1.86 | ||
| Q1 25 | $1.07 | $1.51 | ||
| Q4 24 | $1.04 | $1.63 | ||
| Q3 24 | $1.37 | $0.98 | ||
| Q2 24 | $1.68 | $1.53 | ||
| Q1 24 | $1.85 | $1.24 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $740.0M | $798.0M |
| 总债务越低越好 | — | $27.8B |
| 股东权益账面价值 | $25.3B | $25.8B |
| 总资产 | $54.8B | $80.1B |
| 负债/权益比越低杠杆越低 | — | 1.08× |
8季度趋势，按日历期对齐
现金及短期投资BDXFISV
| Q4 25 | $740.0M | $798.0M | ||
| Q3 25 | $641.0M | $1.1B | ||
| Q2 25 | $735.0M | $999.0M | ||
| Q1 25 | $667.0M | $1.2B | ||
| Q4 24 | $711.0M | $1.2B | ||
| Q3 24 | $1.7B | $1.2B | ||
| Q2 24 | $4.5B | $1.2B | ||
| Q1 24 | $2.3B | $1.2B |
总债务BDXFISV
| Q4 25 | — | $27.8B | ||
| Q3 25 | — | $28.9B | ||
| Q2 25 | — | $28.1B | ||
| Q1 25 | — | $27.0B | ||
| Q4 24 | — | $23.7B | ||
| Q3 24 | — | $24.1B | ||
| Q2 24 | — | $24.4B | ||
| Q1 24 | — | $23.8B |
股东权益BDXFISV
| Q4 25 | $25.3B | $25.8B | ||
| Q3 25 | $25.4B | $25.1B | ||
| Q2 25 | $25.5B | $25.2B | ||
| Q1 25 | $25.2B | $25.9B | ||
| Q4 24 | $25.2B | $27.1B | ||
| Q3 24 | $25.9B | $27.8B | ||
| Q2 24 | $25.9B | $28.2B | ||
| Q1 24 | $25.6B | $28.8B |
总资产BDXFISV
| Q4 25 | $54.8B | $80.1B | ||
| Q3 25 | $55.3B | $79.4B | ||
| Q2 25 | $54.9B | $81.5B | ||
| Q1 25 | $54.5B | $80.4B | ||
| Q4 24 | $54.7B | $77.2B | ||
| Q3 24 | $57.3B | $79.8B | ||
| Q2 24 | $55.6B | $93.4B | ||
| Q1 24 | $54.2B | $92.7B |
负债/权益比BDXFISV
| Q4 25 | — | 1.08× | ||
| Q3 25 | — | 1.15× | ||
| Q2 25 | — | 1.11× | ||
| Q1 25 | — | 1.04× | ||
| Q4 24 | — | 0.88× | ||
| Q3 24 | — | 0.87× | ||
| Q2 24 | — | 0.87× | ||
| Q1 24 | — | 0.82× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $657.0M | $1.9B |
| 自由现金流经营现金流 - 资本支出 | $549.0M | $1.5B |
| 自由现金流率自由现金流/营收 | 10.5% | 28.4% |
| 资本支出强度资本支出/营收 | 2.1% | 8.4% |
| 现金转化率经营现金流/净利润 | 1.72× | 2.40× |
| 过去12个月自由现金流最近4个季度 | $2.6B | $4.3B |
8季度趋势，按日历期对齐
经营现金流BDXFISV
| Q4 25 | $657.0M | $1.9B | ||
| Q3 25 | $1.4B | $1.8B | ||
| Q2 25 | $1.2B | $1.7B | ||
| Q1 25 | $164.0M | $648.0M | ||
| Q4 24 | $693.0M | $2.2B | ||
| Q3 24 | $1.2B | $2.2B | ||
| Q2 24 | $1.3B | $1.3B | ||
| Q1 24 | $514.0M | $831.0M |
自由现金流BDXFISV
| Q4 25 | $549.0M | $1.5B | ||
| Q3 25 | $1.0B | $1.3B | ||
| Q2 25 | $1.0B | $1.2B | ||
| Q1 25 | $35.0M | $313.0M | ||
| Q4 24 | $588.0M | $1.8B | ||
| Q3 24 | $882.0M | $1.8B | ||
| Q2 24 | $1.1B | $993.0M | ||
| Q1 24 | $380.0M | $411.0M |
自由现金流率BDXFISV
| Q4 25 | 10.5% | 28.4% | ||
| Q3 25 | 17.0% | 24.7% | ||
| Q2 25 | 19.0% | 21.5% | ||
| Q1 25 | 0.7% | 6.1% | ||
| Q4 24 | 11.4% | 34.7% | ||
| Q3 24 | 16.2% | 35.2% | ||
| Q2 24 | 22.4% | 19.4% | ||
| Q1 24 | 7.5% | 8.4% |
资本支出强度BDXFISV
| Q4 25 | 2.1% | 8.4% | ||
| Q3 25 | 6.0% | 9.6% | ||
| Q2 25 | 3.2% | 8.7% | ||
| Q1 25 | 2.4% | 6.5% | ||
| Q4 24 | 2.0% | 7.6% | ||
| Q3 24 | 5.4% | 7.7% | ||
| Q2 24 | 3.6% | 6.8% | ||
| Q1 24 | 2.7% | 8.6% |
现金转化率BDXFISV
| Q4 25 | 1.72× | 2.40× | ||
| Q3 25 | 2.75× | 2.28× | ||
| Q2 25 | 2.12× | 1.62× | ||
| Q1 25 | 0.53× | 0.76× | ||
| Q4 24 | 2.29× | 2.37× | ||
| Q3 24 | 2.94× | 3.97× | ||
| Q2 24 | 2.66× | 1.50× | ||
| Q1 24 | 0.96× | 1.13× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
FISV
| Small Business | $1.7B | 32% |
| Products | $1.0B | 19% |
| Digital Payments | $960.0M | 18% |
| Issuing | $792.0M | 15% |
| Enterprise | $587.0M | 11% |
| Processing | $265.0M | 5% |
| Affiliated Entity | $18.0M | 0% |
